Valion Bio
VBIO
1 hedge funds and large institutions have $104K invested in Valion Bio in 2022 Q2 according to their latest regulatory filings, with 0 funds opening new positions, increasing their positions, 1 reducing their positions, and 1 closing their positions.
1.54% less ownership
Funds ownership: 2.1% → 0.56% (-1.5%)
50% less funds holding
Funds holding: 2 → 1 (-1)
68% less capital invested
Capital invested by funds: $329K → $104K (-$225K)
100% less first-time investments, than exits
New positions opened: 0 | Existing positions closed: 1
100% less repeat investments, than reductions
Existing positions increased: 0 | Existing positions reduced: 1
Top Buyers
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Renaissance Technologies
New York
|
-$147K |
| 2 |
KC
Kepos Capital
New York
|
-$97K |
| 3 |
BlackRock
New York
|
-$15K |
| 4 |
TFS
TrustCore Financial Services
Brentwood,
Tennessee
|
-$1K |
VBIO Hedge Fund Activity: Q2 2022 in Review
1 of the 5,959 institutional investors tracked by Wall St. Rank reported a position in Valion Bio (VBIO) for Q2 2022, worth a combined $104K — down 68% from $329K a quarter earlier.
Sellers outnumbered buyers: 1 fund closed out of VBIO and 0 opened new positions — a net loss of 1 holder — while 1 trimmed existing stakes and 0 added.
The largest seller was Renaissance Technologies, cutting an estimated $147K.
- 1 institutional investor held Valion Bio (VBIO) as of Q2 2022, down from 2 in Q1 2022.
- Funds reported $104K of Valion Bio stock for Q2 2022, down 68% quarter-over-quarter.
- 0 funds opened new Valion Bio positions in Q2 2022 and 1 closed out, a net change of -1 holder.
- The largest Valion Bio seller in Q2 2022 was Renaissance Technologies, an estimated $147K sold.
Based on aggregated 13F filings for Q2 2022.